Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia

Background The diagnostic yield for cytomegalovirus (CMV) polymerase chain reaction (PCR) viral load in bronchoalveolar lavage (BAL) or in plasma to diagnose CMV pneumonia in lung transplant recipients remains uncertain and was investigated in a large cohort of consecutive lung transplant recipients. Methods Bronchoscopies within the first year of lung transplantation with CMV detectable in BAL by PCR (ie, viral load, ≥273 IU/mL) were included (66 recipients; 145 bronchoscopies); at each bronchoscopy episode, 2 independent experts reviewed clinical and laboratory information to determine whether the patient at that time fulfilled the criteria for CMV pneumonia per current international recommendations. Corresponding plasma CMV PCR viral load determined at time of the bronchoscopy (n = 126) was also studied. Optimal CMV PCR viral load cutoff for CMV pneumonia diagnosis was determined using receiver operating characteristics. Results CMV was detected in BAL with CMV PCR in 145 episodes, and 34 (23%) of these episodes fulfilled the criteria for CMV pneumonia. The area under the curve-receiver operating characteristics for CMV in BAL was 90% at the optimum cutoff (4545 IU/mL) with a corresponding sensitivity of 91% and specificity of 77% (in plasma the corresponding values were 274 IU/mL, 63% and 76%, respectively). Conclusions CMV PCR viral load in BAL had a high performance to diagnose CMV pneumonia in lung transplant recipients; plasma CMV viral load did not reliably aid as a diagnostic tool.

[1]  V. Miller,et al.  Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  E. Puchhammer-Stöckl,et al.  Intrapulmonary Human Cytomegalovirus Replication in Lung Transplant Recipients Is Associated With a Rise of CCL-18 and CCL-20 Chemokine Levels , 2017, Transplantation.

[3]  B. Pinsky,et al.  Progress in Quantitative Viral Load Testing: Variability and Impact of the WHO Quantitative International Standards , 2016, Journal of Clinical Microbiology.

[4]  A. Heath,et al.  Are We There Yet? Impact of the First International Standard for Cytomegalovirus DNA on the Harmonization of Results Reported on Plasma Samples. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Yusen,et al.  Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients , 2015, Transplantation.

[6]  A. Mocroft,et al.  Clinical Application of Variation in Replication Kinetics During Episodes of Post-transplant Cytomegalovirus Infections , 2015, EBioMedicine.

[7]  A. Caliendo,et al.  Multicenter Evaluation of a Commercial Cytomegalovirus Quantitative Standard: Effects of Commutability on Interlaboratory Concordance , 2013, Journal of Clinical Microbiology.

[8]  R. Booton,et al.  Summary of the British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults , 2013, Thorax.

[9]  A. Humar,et al.  Cytomegalovirus in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  J. Lundgren,et al.  The Time Course of Development and Impact From Viral Resistance Against Ganciclovir in Cytomegalovirus Infection , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  T. Welte,et al.  Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients , 2013, Transplant infectious disease : an official journal of the Transplantation Society.

[12]  L. Cardeñoso,et al.  An International Multicenter Performance Analysis of Cytomegalovirus Load Tests , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Caliendo,et al.  Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. , 2013, Transplantation.

[14]  E. Arbustini,et al.  Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients. , 2012, The new microbiologica.

[15]  J. Golden,et al.  Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[16]  L. Snyder,et al.  Is Prevention the Best Treatment? CMV After Lung Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  J. Maurer Cytomegalovirus Replication Within the Lung Allograft Is Associated With Bronchiolitis Obliterans Syndrome , 2012 .

[18]  S. Chow,et al.  Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation , 2010, Annals of Internal Medicine.

[19]  E. Puchhammer-Stöckl,et al.  Cytomegalovirus DNA Load Patterns Developing After Lung Transplantation Are Significantly Correlated With Long-Term Patient Survival , 2009, Transplantation.

[20]  E. Arbustini,et al.  Preemptive Therapy for Systemic and Pulmonary Human Cytomegalovirus Infection in Lung Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  A M Caliendo,et al.  Interlaboratory Comparison of Cytomegalovirus Viral Load Assays , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  G. Lang,et al.  Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  J. Carlsen,et al.  Interstitial Inflammatory Lesions of the Pulmonary Allograft: A Retrospective Analysis of 2697 Transbronchial Biopsies , 2008, Transplantation.

[24]  E. Puchhammer-Stöckl,et al.  Relationship between Cytomegalovirus DNA Load in Epithelial Lining Fluid and Plasma of Lung Transplant Recipients and Analysis of Coinfection with Epstein-Barr Virus and Human Herpesvirus 6 in the Lung Compartment , 2006, Journal of Clinical Microbiology.

[25]  B. Bekele,et al.  Clinical Utility of Cytomegalovirus Viral Load in Bronchoalveolar Lavage in Lung Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  G. Snell,et al.  Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. , 2004, The Journal of infectious diseases.

[27]  M. Salizzoni,et al.  Quantitation of cytomegalovirus DNA by the polymerase chain reaction as a predictor of disease in solid organ transplantation. , 2004, Journal of medical virology.

[28]  S. Arrigain,et al.  Correlation between Viral Loads of Cytomegalovirus in Blood and Bronchoalveolar Lavage Specimens from Lung Transplant Recipients Determined by Histology and Immunohistochemistry , 2004, Journal of Clinical Microbiology.

[29]  E. Trulock,et al.  Relationship of cytomegalovirus viral load in blood to pneumonitis in lung transplant recipients. , 2001, Transplantation.

[30]  S. Olofsson,et al.  Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. , 2000, Chest.

[31]  C. Sabin,et al.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation , 2000, The Lancet.

[32]  R. Rubin,et al.  Infection in organ-transplant recipients. , 1998, The New England journal of medicine.

[33]  A. Mehta,et al.  Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  J. Bernaudin,et al.  Predictive value of cytomegalovirus DNA detection by polymerase chain reaction in blood and bronchoalveolar lavage in lung transplant patients. , 1997, Transplantation.

[35]  Z. Loewy,et al.  COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR. , 1996, Clinical chemistry.

[36]  P. Cagle,et al.  THE DIAGNOSIS OF CMV PNEUMONITIS IN LUNG AND HEART/LUNG TRANSPLANT PATIENTS BY PCR COMPARED WITH TRADITIONAL LABORATORY CRITERIA , 1993, Transplantation.

[37]  B. Griffith,et al.  Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. , 1992, The American review of respiratory disease.